Link copied to clipboard!

Care.fi acquires Aldun to deliver a unified, patient-first discharge experience

IMT News Desk
IMT News Desk
· 2 min read

Care.fi aims to to scale to 300 Hospital units and 1 lakh monthly discharges to save 10 lakh+ admin hours and deliver a unified, patient-first experience from pre-auth to settlement

Care.fi, a healthcare-focussed fintech founded by Vikrant Agrawal and Sidak Singh, announced its acquisition of Aldun, a discharge-automation platform known for enabling near-instant, 10-minute patient discharges. Aldun currently supports around 10,000 discharges each month across hospital networks including Aster, Apollo, Manipal, Sir Ganga Ram, Fortis, KIMS, Narayana, and Cloudnine, impacting over 1 lakh lives and saving hospitals more than 10 lakh administrative hours.

Care.fi plans to scale the combined solution to 300 hospital units and approximately 1 lakh monthly discharges, creating a unified and transparent experience from admission to settlement.

By integrating Aldun’s last-mile orchestration with Care.fi’s revenue-cycle and financing rails, the acquisition addresses a system-wide bottleneck, slow, manual discharge, unlocking measurable capacity and cash flow for providers. Hospitals will benefit from higher bed-turnover, faster claims closure, and reduced denials, while finance teams gain real-time visibility into receivables and working capital. For the broader ecosystem, faster discharges will increase daily effective capacity without new capex, improving access and service levels.

“Discharge is the last mile of care and the first memory a family takes home. By bringing Aldun into the Care.fi fold, we’re turning hours into minutes and queues into capacity. Coupled with our RCM and financing rails, including our single-window claims platform, hospitals get one operating layer for faster discharge, cleaner books and a measurably better patient experience,” said Vikrant Agrawal, Co-founder, Care.fi.

Sidak Singh, Co-founder, Care.fi, says, “At scale, discharge delays aren’t just an operational issue, they distort cashflows, capacity planning and patient confidence. This acquisition lets us redesign discharge as a predictable, system-level outcome rather than a daily firefight. By unifying financing, claims and settlement into one workflow, we’re helping hospitals release locked capacity, accelerate collections, and deliver a consistent patient experience as they grow across cities and care settings.”

Read Next

Granules India posts Rs 13,879 million revenue from operations at Q3FY26
Finance
January 28, 2026

Granules India posts Rs 13,879 million revenue from operations at Q3FY26

Net debt stood at Rs 10,151 million and net debt to EBITDA at 0.91x Granules India has announced its financial results for the quarter ended December 31, 2025. Revenue from Operations of Q3FY26 stood at Rs 13,879 million, a growth of 22 per cent YoY driven by Finished Dosages (FD) segment in North America and […]
Article by: IMT News Desk
OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26
Finance
January 28, 2026

OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26

Impacted by delayed semaglutide approvals in Canada OneSource has posted the Q3FY26 results. Revenues were at Rs 2,903 million, down 26 per cent YoY, impacted by delayed semaglutide approvals in Canada. The EBITDA was at Rs 173 million, down 88 per cent YoY, due to lower revenue in the quarter and largely fixed cost base. […]
Article by: IMT News Desk
Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr
Finance
January 27, 2026

Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr

Reported revenue dips to Rs 932 crore in the same quarter Syngene International announced financial results for the third quarter of FY26. Peter Bains, Managing Director and CEO, Syngene International, said, “Our Q3 performance reflects the ongoing impact related to a single product from one of our large-molecule biologics clients. Outside of this factor, the […]
Article by: IMT News Desk
Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427
Finance
January 27, 2026

Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427

Sigachi’s entry into CF APIs positions the company in a structurally strong and innovation-led therapeutic segment with long-term demand visibility Sigachi Industries announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. The development marks […]
Article by: IMT News Desk